News | August 05, 2025
Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Upgrades 2025 full-year CDMO sales and margin outlook
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated
